Moreover, Haydon et al. [92] showed that PPARγ agonists are excellent therapy for human osteosarcoma, the biggest metastasis problem in many late carcinomas, while Koumanis et al. [93] looked at correlations between overweight groups and mortality in association with PPAR G2 Pro12Ala genotypes. Here, PPARA is linked to osteosarcoma.